竞争惨烈啊 你还在做这27个药吗?

  • 药品,竞争,27
  • 远齐微信

这些药品有多少个竞争对手?国家药监总局网站公布,以下表中的27种相同活性成分、相同给药途径药品批准文号数量在300至500个之间。

惨烈啊,兄弟,你还在做这些药吗?


序号通用名给药途径
1维生素B12注射
2庆大霉素注射
3维生素B2口服
4琥乙红霉素口服
5马来酸氯苯那敏/双氯芬酸/人工牛黄口服
6吡哌酸口服
7阿莫西林口服
8头孢哌酮钠/舒巴坦钠注射
9阿奇霉素口服
10小儿氨酚黄那敏口服
11林可霉素口服
12利巴韦林注射
13维生素B6注射
14利巴韦林口服
15头孢拉定口服
16马来酸氯苯那敏口服
17右旋糖酐40注射
18头孢呋辛注射
19干酵母口服
20硝苯地平口服
21阿司匹林/非那西丁/咖啡因口服
22卡托普利口服
23头孢他啶注射
24头孢曲松注射
25地塞米松磷酸钠注射
26小儿复方磺胺甲恶唑口服
27甘露醇注射


This link:http://www.chemcd.com/news/8101.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.